NASDAQ · ALNY
Alnylam Pharmaceuticals, Inc.
$174.00-$58.40 (-25.13%)
Alnylam Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.73% below the high.
Loading market information…
NASDAQ · VRTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vertex Pharmaceuticals Incorporated’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vertex Pharmaceuticals Incorporated’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of $4.80. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vertex Pharmaceuticals Incorporated’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 5, 2025 | $4.06-4.47% vs estimate | $2.77B-3.2% vs estimate |
|---|
| Q4 2024 | Feb 10, 2025 | $3.98-1.0% vs estimate | $2.91B+4.59% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | $4.38+5.8% vs estimate | $2.77B+3.22% vs estimate |
|---|
THE ANALYST VIEW
56 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 14 contributors · Median target $601.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$174.00-$58.40 (-25.13%)
Alnylam Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.73% below the high.
$70.73-$0.09 (-0.13%)
BridgeBio Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.29% below the high.
$57.49+$1.49 (+2.66%)
BioMarin Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.01% below the high.
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$64.46+$1.44 (+2.28%)
PTC Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
$54.26+$0.15 (+0.28%)
CRISPR Therapeutics AG’s quoted price sits in the lower half of its reported 52-week range, 17.76% below the high.
$28.84+$0.06 (+0.21%)
Beam Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.62% below the high.
$19.23-$0.09 (-0.47%)
Sarepta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.43% below the high.
